Systemic antiviral agents

Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print

Volumn , Issue , 2012, Pages 121-134

  Magel, George D ^a   Haitz, Kassie A ^b   Lapolla, Whitney J ^b   DiGiorgio, Catherine M ^c   Mendoza, Natalia ^b   Tyring, Stephen K ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Clinical Studies   (United States)

^c Dermatological Association of Texas   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894481753     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2003-7.00010-8     Document Type: Chapter

References (94)

1. Whitley RJ, Gnann JW Herpes simplex viruses. Mucocutaneous manifestations of viral diseases 2010, 65-97. Informa Healthcare, London. 2nd ed. S.K. Tyring, A.Y. Moore, O. Lupi (Eds.).
2. Wagstaff AJ, Faulds D, Goak L Acyclovir, a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47:153-205.
3. Herne K, Cirelli R, Lee P, et al. Advances in antiviral therapy. Curr Opin Dermatol 1996, 3:195-201.
4. Furman P, St Clair MH, Fyfe JA, et al. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and it triphosphate. J Virol 1979, 32:72-77.
5. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996, 124:8-15.
6. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003, 102:1396-1403.
7. Goldberg LH, Kaufman R, Kurtz TO, et al. The acyclovir study group. Long-term suppression of recurrent genital herpes with acyclovir : a 5-year benchmark. Arch Dermatol 1993, 129:582-587.
8. Spruance SL Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993, 1(suppl):27-32.
9. Ioannidis JPA, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998, 178:349-359.
10. Heng MC, Heng SY, Allen SG Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994, 343:255-258.
11. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
12. Reyes M, Shaik NS, Graber JM, et al. Acyclovir -resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2002, 163(1):76-80.
13. Thandi A, Tyring SK Newer aspects of herpes virus infections. Current opinions in dermatology 1997, 42-50. Rapid Science, Philadelphia. M.V. Dahl (Ed.).
14. Klassen T, Hartling L, Wiebe N, et al. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev 2005, (4). CD002980.
15. Smego RA, Asperilla MO Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol 1991, 78:1112-1116.
16. Huff JC, Drucker JL, Clemmer A, et al. Effects of oral acyclovir on pain resolution in herpes zoster. A reanalysis. J Med Virol 1993, 1(Suppl):93-96.
17. Lemak MA, Duvic M, Bean SF Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol 1986, 15:50-54.
18. Schofield JK, Tatnall FM, Leigh IM Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993, 128:542-545.
19. Tatnall FM, Schofield JK, Leigh IM A double-blind placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995, 132:267-270.
20. Fife KH, Barbarash RA, Rudolph T, et al. Valacyclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997, 24:481-486.
21. Leone PA, Trottier S, Miller JM A comparison of oral valacyclovir 500 mg twice daily for three or five days in the treatment of recurrent genital herpes 15-18 May 1998, and the International Valacyclovir Study Group, ICID, Boston, USA.
22. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Eng J Med 2004, 350:11-20.
23. Martens MG, Fife KH, Leone PA, et al. Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. Infect Dis Obstet Gynecol 2009, 105376.
24. Lawrence AG, Bell AR, International Valacyclovir HSV Study Group. Valacyclovir for prevention of recurrent herpes simplex virus infection in HIV-infected individuals - a double-blind controlled trial. 8th ECCMID, 1997.
25. Conant MA, Schacker TW, Murphy RL, et al. Valacyclovir versus acyclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002, 13:12-21.
26. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005, 79:317.
27. Spruance SL, Jones TM, Blatter M, et al. High-dose, short duration, early valacyclovir therapy for the episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003, 47:1072-1080.
28. Baker D, Eisen D Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind placebo-controlled studies. Cutis 2003, 71:239-242.
29. Beeson WH, Rachel JD Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg 2002, 28:331-334.
30. Tyring SK Advances in the treatment of herpes virus infections: the role of famciclovir. Clin Ther 1998, 20:661-670.
31. Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994, 33:119-127.
32. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative famciclovir genital herpes research group. JAMA 1998, 280:887-892.
33. Tyring SK, Diaz-Mitoma F, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: The combined data from two randomized controlled trials. J Cutan Med Surg 2003, 7:449-454.
34. Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999, 179:303-310.
35. Bartlett B, Tyring S, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008, 43(2):190-195.
36. Alster TS, Nanni CA Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999, 25:242-246.
37. Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000, 14:1211-1217.
38. Schacker T, Hu H, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind placebo-controlled trial. Ann Intern Med 1998, 128:21-28.
39. Enzensberger R, Braun W, July C, et al. Prevalence of antibodies to human herpes viruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection 1991, 3:140-145.
40. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280:61-66.
41. Tyring SK, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1995, 123:89-96.
42. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9:863-869.
43. Tyring SK, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomized acyclovir controlled study. Br J Ophthalmol 2001, 85:576-581.
44. Tyring SK, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001, 19:13-22.
45. Morfin F, Thouvenot D Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003, 26:29-37.
46. Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir (abstract H12). American Society for Microbiology, 35th ICAAC meeting. San Francisco, California, September, 1995.
47. Sacks SL, Aoki F, Diaz-Mitoma F, et al. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes. JAMA 1996, 276:44-49.
48. Stranska SR, Schuurman SR, Nienhuis E, et al. Survey of acyclovir resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005, 32:7-18.
49. Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Retrieved from, (November 2011). http://wonder.cdc.gov/wonder/prevguid/m0042990/m0042990.asp.
50. Hicks LD, Cook-Norris RH, Mendoza N, et al. Family history as a risk factor for herpes zoster: a case-controlled study. Arch Dermatol 2008, 144(5):603-608.
51. Wu J, Huang D, Pang K, et al. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. J Am Acad Dermatol 2004, 50:495-528.
52. Oxman M, Levin M, Johnson G, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
53. Straus S, Wald A, Kost R, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176:1129-1134.
54. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999, 282:331-340.
55. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661. GlaxoSmithKline Herpes Vaccine Efficacy Study Group.
56. Casanova G, Cancela R, Alonzo L, et al. A double blind study of the efficacy and safety of the ICP10PK vaccine against recurrent genital HSV-2 infections. Cutis 2002, 70:235-239.
57. Morgan MC, Bartlett BL, Cockerell CJ, Cohen PR Cutaneous manifestation of HIV infection. Mucocutaneous manifestations of viral diseases. Second Edition 2010, 263-339. Informa Healthcare, London. S.K. Tyring, A.Y. Moore, O. Lupi (Eds.).
58. Kaplan MH, Sadick N, McNutt NS, et al. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1987, 16:485.
59. Zalla MJ, Su WP, Fransway AF Dermatologic manifestations of human immunodeficiency virus infection. Mayo Clin Proc 1992, 67:1089.
60. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990, 322:941-949.
61. Mofenson LM Centers for Disease Control and Prevention, U.S. Public Health Service Task Force. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002 Nov 22, 51(RR-18):1-38.
62. Torres RA, Barr MR, McIntyre KI, et al. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS 1995, 6:19-26.
63. Cammack N Lamivudine in the therapy of HIV infection. Int Antiviral News 1996, 4:127-128.
64. Shuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immune deficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. J Infect Disease 1995, 171:1431.
65. Staszewski S Coming therapies: abacavir. Int J Clin Pract 1999, 103(Suppl):35-38.
66. Foster RH, Faulds D Abacavir. Drugs 1998, 55:729-738.
67. Clay PG, Rathbun RC, Slater LN Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother 2000, 34:247-249.
68. Chang Y, Tyring SK Therapy of HIV infection. Dermatol Ther 2004, 17:449-464.
69. Antiviral Briefs. AIDS Patient Care STDS 2004, 18(10):614.
70. Dando TM, Wagstaff AJ Emtricitabine/tenofovir disoproxil fumarate. Drugs 2004, 64(18):2075-2082.
71. Goldschmidt RH, Moy A Antiretroviral drug treatment for HIV/AIDS. Am Fam Phys 1996, 54:574-580.
72. Wynn P Class of AIDS drugs boost combination therapy approach. Dermatol Times 1996, 17:33.
73. Bellman PC Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998, 12(Suppl A):S165-S174.
74. Rotunda A, Hirsh RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003, 83:1-9.
75. Ruiz N Clinical history of efavirenz. Int J Clin Pract 1999, 103(Suppl):3-7.
76. Watts DH Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002, 346:1879.
77. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002, 162:355.
78. McDonald CK, Kurtzkes DR Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997, 157:951-959.
79. Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: Preliminary safety and activity data. In: Program and Abstracts of the 11th International Conference on AIDS (abstract Th.B 934). Vancouver, British Columbia, July 1996.
80. Gathe J, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine vs stavudine alone (abstract MB 413). In: Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, July 1996.
81. Moyle GJ, Youle M, Higgs C, et al. Extended follow-up and safety and activity of Agouron's HIV protease inhibitor from the UK phase I/II dose finding study (abstract MB 173). In: Program and Abstracts of the 11th International Conference on AIDS. Vancouver, British Columbia, July 1996.
82. Adkins JC, Faulds D Amprenavir. Drugs 1998, 55:837-844.
83. Tipranavir (Aptivus) for HIV. Med Lett Drugs Ther 2005, 47:83-84.
84. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 2004, 18:775-779.
85. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004, 23:923-930.
86. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003, 139:313-320.
87. Raffi F Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics. Med Mal Infect 2004, 34:3-7.
88. Raffi F Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors in intracellular penetration of human immunodeficiency virus (HIV) type 1. Med Mal Infect 2004, 34:8-17.
89. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1 infected persons in 10 US cities. J Infect Dis 2004, 189:2174-2180.
90. De Clercq E New developments in anti-HIV chemotherapy. Curr Med Chem 2001, 8:1543-1572.
91. Rusconi S, Scozzafava A, Mastrolorenzo A, et al. New advances in HIV entry inhibitors development. Curr Drug Targets Infect Disord 2004, 4:339-355.
92. Shelton DL Vaccines now being tested around the world. Am Med News January 20, 1997.
93. AIDS vaccine moves into phase 3 trials (Medical News & Perspectives). JAMA 1998, 280:7-8.
94. McCarthy M HIV vaccine fails in phase 3 trial. Lancet 2003, 361:755-756.